US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

11.90 -0.05 (-0.42%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
News headline image
Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch ↗
Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data ↗
Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances ↗
Compass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter,... 
Via MarketBeat
Topics Cannabis Government
Compass Pathways (NASDAQ:CMPS) Shares Plunge 42% After Q2 Report Despite Narrower-Than-Expected Loss ↗
Via Chartmill
News headline image
Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears ↗
Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a... 
Via MarketBeat
Topics Cannabis Government
News headline image
COMPASS Pathways (CMPS) Q2 2026 Earnings Call Transcript ↗
COMP360 shows 39% response rate; commercial launch targeted for H1 2027. 
Via The Motley Fool
Topics Earnings
News headline image
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances ↗
Compass Pathways (NASDAQ:CMPS) said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth... 
Via MarketBeat
Topics Government
News headline image
Compass Pathways Q2 Earnings Call Highlights ↗
Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its new drug application, or NDA, filing for COMP360 in treatment-resistant depression in the fourth quarter of 2026, following... 
Via MarketBeat
Topics Cannabis Earnings Government
News headline image
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet. ↗
Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market. 
Via The Motley Fool
Topics ETFs Government
News headline image
Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know. ↗
Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline. 
Via The Motley Fool
News headline image
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up ↗
Compass Pathways (NASDAQ:CMPS) said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins ↗
Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass (CMPS) Q1 2026 Earnings Transcript ↗
Compass (CMPS) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Compass Pathways Q1 Earnings Call Highlights ↗
Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for... 
Via MarketBeat
Topics Cannabis Earnings Government
News headline image
These 3 Psychedelic Stocks Activated After Trump's Executive Order ↗
Via MarketBeat
Topics Government
News headline image
Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About ↗
Compass Pathways is already in the final stage of development on a psychedelic medicine to treat depression. 
Via The Motley Fool
Topics Government
After Fifteen Years, Tim Cook Steps Down, Wall Street Steps Back, Oil Steps Up ↗
Via Chartmill
News headline image
This 4/20, Wall Street Is Betting on More Than Marijuana ↗
Via MarketBeat
Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
This Psychedelic Biotech Stock Is Soaring After Trump Executive Order ↗
COMPASS Pathways PLC (NASDAQ:CMPS) shares are soaring on Monday after President Donald Trump issued an executive order directing federal health agencies to speed up the review process for... 
Via Benzinga
Topics Government
What's going on in today's session ↗
Via Chartmill
News headline image
Why Compass Pathways Stock Rocketed 40% Today ↗
Compass Pathways may be the first to benefit from an accelerated approval process. 
Via The Motley Fool
Topics Government
News headline image
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗
Trump is easing approval for psychedelic treatments for mental disorders. 
Via The Motley Fool
Topics Government
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
The Psychedelic Revolution in Mental Healthcare ↗
Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, discuss their new book, Psychedelic Therapy: A Revolutionary Approach to Restoring Mental Health and... 
Via The Motley Fool
News headline image
The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics
Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more... 
Via Finterra
Topics Cannabis Initial Public Offering Intellectual Property
News headline image
Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise ↗
Via MarketBeat
News headline image
Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
CMPS Stock Slumps Premarket As $150M Offering Cuts Into Psychedelic Trial Buzz ↗
The company CMPS is planning to seek FDA guidance on a rolling review and target a New Drug Application submission in the fourth quarter. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >